156 filings
Page 3 of 8
6-K
wfw ym1v0k
6 Feb 23
CureVac Announces Proposed Public Offering of Common Shares
4:31pm
6-K
luuqh0q0ijm4k1j1uos
1 Feb 23
CureVac Welcomes Myriam Mendila as New Chief Development Officer
4:10pm
6-K
60j6b5
31 Jan 23
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis
4:05pm
6-K
1h5mx 7rd
30 Jan 23
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
4:10pm
6-K
cg5z4f9v65s8cuevj1
9 Jan 23
Current report (foreign)
4:11pm
6-K
b1jp0o5
6 Jan 23
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
4:10pm
6-K
klt asq84k90shjar
14 Dec 22
Current report (foreign)
4:23pm
6-K
2azk4 gy1s
17 Nov 22
Current report (foreign)
5:30pm
6-K
dy28c1m5xk468
17 Nov 22
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
5:26pm
6-K
xlbu3
14 Nov 22
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
7:00am
6-K
ftgyn0g9o5hxk003
18 Aug 22
Current report (foreign)
4:20pm
6-K
u25ixifu
18 Aug 22
Current report (foreign)
4:15pm
6-K
xk1 fc1li
18 Aug 22
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
4:10pm
6-K
6tj 7o52e916l4
5 Jul 22
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
4:15pm
6-K
ical2l409ar zgi
27 Jun 22
Current report (foreign)
4:16pm
6-K
ydjr 37wcyqo20sqr6i
22 Jun 22
CureVac Announces Voting Results of General Meeting
4:15pm
6-K
266felohj0
8 Jun 22
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
4:21pm
6-K
5qj lgh7vgfpo219z5jq
8 Jun 22
CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen
4:15pm
6-K
ytd9 f2dk2ndf
1 Jun 22
Current report (foreign)
4:15pm
6-K
8mx6aeh985l3ffhjxjk
25 May 22
Current report (foreign)
5:14pm